Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1α expression and secretion in mouse myeloma cells

Cancer Science

Volumn 99, Issue 1, 2008, Pages 152-158

  Tsubaki, Masanobu ^a   Kato, Chisato ^a   Nishinobo, Minori ^a   Ogaki, Mitsuhiko ^a   Satou, Takao ^b   Ito, Tatsuki ^b   Kusunoki, Takashi ^b   Fujiwara, Kimiko ^c   Yamazoe, Yuzuru ^c   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KINDAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MINODRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITROGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CANCER GROWTH; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; INHIBITION KINETICS; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BUTADIENES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOKINE CCL3; CHROMONES; DIPHOSPHONATES; I-KAPPA B PROTEINS; IMIDAZOLES; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; MULTIPLE MYELOMA; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYISOPRENYL PHOSPHATES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SESQUITERPENES;

EID: 36949039020     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00651.x     Document Type: Article

References (24)

1. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004; 19: 2065-77.
2. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97: 3349-53.
3. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101: 3568-73.
4. Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671-5.
5. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106-9.
6. Choi SJ, Oba Y, Gazitt Y et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001; 108: 1833-41.
7. Oba Y, Lee JW, Ehrlich LA et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005; 33: 272-8.
8. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17: 1921-5.
9. Winding B, Misander H, Sveigaard C et al. Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis. J Cancer Res Clin Oncol 2000; 126: 631-40.
10. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54.
11. Fleisch H. Bisphosphonate: Mechanisms of action. Endocr Rev 1998; 19: 80-100.
12. Shipman CM, Croucher PI, Graham R, Russell G, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294-7.
13. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 2003; 73: 2655-64.
14. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 2003; 15: 719-27.
15. Yamagishi S, Abe R, Inagaki Y et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165: 1865-74.
16. Gordon S, Helfrich MH, Sati HI et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002; 119: 475-83.
17. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res 2005; 65: 4971-4.
18. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4: 499-511.
19. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of toll-like receptor signaling. Cell 2002; 110: 191-202.
20. Xu H, An H, Yu Y, Zhang M, Qi R, Cao X. Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/ tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. J Biol Chem 2003; 278: 36334-40.
21. Ciesielski CJ, Andreakos E, Foxwell BM, Feldmann M. TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. Eur J Immunol 2002; 32: 2037-45.
22. Segawa H, Kimura S, Kuroda J et al. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk Res 2005; 29: 451-7.
23. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13: 7-26.
24. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126-35.